If you have been reading about amino acid sequence and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-29. Numbers and descriptions here follow the published literature rather than marketing material.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Water in the deep ocean takes about 1,000 years to circulate back through surface waters, and so the surface waters contain a combination of older water, with depleted 14C, and water recently at the surface, with 14C in equilibrium with the atmosphere. Creatures living at the ocean surface have the same 14C ratios as the water they live in, and as a result of the reduced 14C/12C ratio, the radiocarbon age of marine life is typically about 400 years. Organisms on land are in closer equilibrium with the atmosphere and have the same 14C/12C ratio as the atmosphere. These organisms contain about 1.3% of the carbon in the reservoir; sea organisms have a mass of less than 1% of those on land and are not shown in the diagram. Accumulated dead organic matter, of both plants and animals, exceeds the mass of the biosphere by a factor of nearly 3, and since this matter is no longer exchanging carbon with its environment, it has a 14C/12C ratio lower than that of the biosphere.
Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug. In April 2016, the U.S. FDA added a warning about increased risk of heart failure. This was based on data in an article that concluded "DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes."
The report acknowledged that "volunteers or mercenaries" entered Georgia from Russia before the Georgian military operation, adding that "some" non-peacekeeping Russian troops were present in South Ossetia and that Russian air force was already acting against Georgia before the public decision to participate in the conflict was made by the Russian leadership at 14:30 on 8 August.
Luisa DiPietro is a faculty member at the University of Illinois at Chicago College of Dentistry. She is Director of the Center for Wound Repair and Tissue Regeneration and a Professor of Periodontics for the College. DiPietro's interests in wound healing focus on the effects of aging and inflammation on scarring during healing. She investigates critical differences in inflammation and angiogenesis between oral versus cutaneous wounds that ultimately result in rapid, nonscarring healing in mucosa. From 2010 to 2011, she served as the president of the Wound Healing Society. In 2015, she was named a University Scholar of the University of Illinois. DiPietro received her PhD in immunology and DDS from the University of Illinois at Chicago.
=== Games about the Cold War === Twilight Struggle is a 2005 card-based board game by GMT Games that depicts the events of the entire Cold War, starting from Joseph Stalin to Ronald Reagan. The game was turned into a video game in 2016.
Sources: en.wikipedia.org
In 2017, Freeman appeared in two comedies: Going in Style and Just Getting Started. The first one is a remake of the 1979 film with the same name, co-starring Michael Caine and Alan Arkin; in it they play bank robbers after their pensions are canceled. It opened to a mixed response; The Telegraph's Robbie Collin thought the trio of actors looked tired before the end of it. Just Getting Started, in which Freeman starred with Tommy Lee Jones and Rene Russo, was critically panned by reviewers. The plot follows an ex-FBI agent (Jones) who must put aside his personal feud with a former mob lawyer (Freeman) at a retirement home when the mafia comes to kill the pair. Freeman also hosted the National Geographic The Story of God with Morgan Freeman and The Story of Us with Morgan Freeman, in 2016 and 2017, respectively. In 2018, Freeman narrated Alpha, a historical drama set in the last ice age. He then starred in Disney's The Nutcracker and the Four Realms, a retelling of E. T. A. Hoffmann's short story "The Nutcracker and the Mouse King" and Marius Petipa's and Pyotr Ilyich Tchaikovsky's ballet The Nutcracker. Finally he had an uncredited role as Jerome in the biographical drama Brian Banks, a high-school football player who was falsely accused of rape and upon his release attempted to fulfill his dream of making the NFL. In 2019, Freeman starred opposite John Travolta in The Poison Rose, an adaptation of the novel by Richard Salvatore.
== Occurrence == Obsidian is found near volcanoes in locations which have undergone rhyolitic eruptions. It can be found in Argentina, Armenia, Azerbaijan, Australia, Canada, Chile, Georgia, Ecuador, El Salvador, Greece, Guatemala, Hungary, Iceland, Indonesia, Italy, Japan, Kenya, Mexico, New Zealand, Papua New Guinea, Peru, Russia, Scotland, the Canary Islands, Turkey and the United States. Obsidian flows which are so large that they can be hiked on are found within the calderas of Newberry Volcano (Big Obsidian Flow, 700 acres) and Medicine Lake Volcano in the Cascade Range of western North America, and at Inyo Craters east of the Sierra Nevada in California. Yellowstone National Park has a mountainside containing obsidian located between Mammoth Hot Springs and the Norris Geyser Basin, and deposits can be found in many other western U.S. states including Arizona, Colorado, New Mexico, Texas, Utah, and Washington, Oregon and Idaho.
The Spy Who Came In from the Cold is a 1965 British spy film directed and produced by Martin Ritt, adapted by Paul Dehn and Guy Trosper from the 1963 novel by John le Carré. It stars Richard Burton, Claire Bloom, and Oskar Werner, and features Sam Wanamaker, Cyril Cusack, Rupert Davies, George Voskovec, and Peter van Eyck in supporting roles. The film depicts British MI6 agent Alec Leamas' (Burton) mission as a faux defector who is given the task of sowing damaging disinformation about a powerful East German intelligence officer (Werner). As part of a charade, Leamas is apparently dismissed from the British secret intelligence service and becomes an embittered alcoholic. He also strikes up a relationship with Nan Perry (Bloom), a British communist. He is soon approached by East German agents in Britain, and he allows himself to be recruited and taken to continental Europe to sell his secrets for money. The plots of the rival spy agencies unfold, and prove more complicated than Leamas expected. The Spy Who Came In from the Cold was a box-office success, receiving positive reviews and several awards, including four BAFTA Awards for Best British Film, Best Actor (for Burton), Best Cinematography, and Best Production Design. For their performances, Burton was also nominated for the Academy Award for Best Actor while Werner won the Golden Globe Award for Best Supporting Actor. The film was named one of the top ten films of 1965 by the National Board of Review in the United States.
=== Border controls and traffic restrictions === Switzerland temporarily reintroduced controls at the border with France from 10 to 19 June 2026. The Federal Council stated that although the summit would take place in France, Geneva, Lausanne and the wider Lake Geneva region were exposed to security risks connected with the event. In the canton of Geneva, only seven road border crossings with France remained open from 12 to 18 June 2026: Anières, Moillesulaz, Thônex-Vallard, Bardonnex, Perly, Meyrin and Ferney-Voltaire. Crossings through railway stations and Geneva Airport remained authorised, but other crossings, including for cyclists and pedestrians, were restricted. Geneva authorities also warned of disruption to public transport, road traffic, as well as temporary restrictions affecting some public spaces. A priority access sticker system, known as a macaron, was introduced for eligible essential workers and residents. Geneva authorities stated that access to Switzerland remained possible without one, subject to controls and available crossings. Additional traffic restrictions were introduced on the Geneva motorway network, including restrictions on the A1 motorway between Geneva Airport and the Bardonnex customs crossing during the summit period.
Sources: en.wikipedia.org
=== Interval between sharpenings === A saw chain must be sharpened when the saw starts to vibrate or cuts poorly. The operator can feel the vibrations in the handles and the engine runs harder while cutting.
==== Puberty ==== For girls born in the United States, the average age of the onset of puberty has been steadily falling since the late twentieth century. According to a 2019 meta-analysis the age of pubertal onset among girls was between 8.8 and 10.3 years in the United States. Early puberty is associated with a variety of mental health issues (such as anxiety and depression), early sexual activity, venereal diseases, alcoholism, and substance abuse, among other problems. Furthermore, factors known for prompting mental health problems—early childhood stress, absent fathers, domestic conflict, and low socioeconomic status—are themselves linked to early pubertal onset. According to Dr. Dr. Shruthi Mahalingaiah, body-mass index is a strong predictor of precocious puberty. Possible causes of early puberty could be positive, namely improved nutrition, or negative, such as obesity, stress, trauma, exposure to hormone-disrupting chemicals, air pollutants, heavy metals. Girls of African ancestry on average enter puberty first, followed by those of Hispanic, European, and Asian extraction, in that order. But African-American girls are less likely to face the negative effects of puberty than their counterparts of European descent.
== Further reading == Abbott, Andrew (2001). Chaos of Disciplines. University of Chicago Press. ISBN 978-0-226-00101-2. Oleson, Alexandra; Voss, John (1979). The Organization of knowledge in modern America, 1860–1920. Johns Hopkins University Press. ISBN 0-8018-2108-8. US Department of Education Institute of Education Sciences. Classification of Instructional Programs (CIP). National Center for Education Statistics.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.